Hormone serum levels during oral cimetidine treatment of patients with peptic ulcers.
Radioimmunoassayable basal serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (hPRL), 17 beta-estradiol (E2) and testosterone (T) were estimated in a total of 68 patients, who were treated because of peptic ulcer with 1 g cimetidine per day. 37 patients were male and 31 were female subjects, respectively. Hormone serum levels were assayed before and 4 to 6 weeks after start of therapy. A significant increase of LH serum levels (p less than 0.025) and a significant decrease of hPRL (p less than 0.025) was noted in the male subjects during therapy. Similarly, a decrease of hPRL serum levels (p less than 0.001) was registered in the female subjects during treatment with 1 g cimetidine per day. All other hormone serum levels in both female and male subjects remained unchanged. The present data combine to suggest that 1 g cimetidine per day does not provoke hyperprolactinemia. In addition, cimetidine at the dose used does not interfere with other hormones of the hypothalamus-pituitary-gonadal axis and therefore, cannot be considered, responsible for endocrine disorders during treatment with cimetidine.
D000284:Administration, Oral; D002927:Cimetidine / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006146:Guanidines / Q000627:therapeutic use*; D006728:Hormones / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010437:Peptic Ulcer / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood
D006146:Guanidines; D006728:Hormones; D013739:Testosterone; D004958:Estradiol; D002927:Cimetidine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone